TheraRadar

Pharma Intelligence, Simplified

Data updated: Mar 10, 2026

PROSCAR

FINASTERIDE 5-alpha Reductase Inhibitors
Oncology Approved 1992-06-19
3
Indications
--
Phase 3 Trials
1
Priority Reviews
33
Years on Market

Details

Status
Prescription
First Approved
1992-06-19
Routes
ORAL
Dosage Forms
TABLET

Companies

Active Ingredient: FINASTERIDE

PROSCAR Approval History

Loading approval history...

What PROSCAR Treats

2 indications

PROSCAR is approved for 2 conditions since its original approval in 1992. These indications span multiple therapeutic areas including oncology, immunology, and more.

  • Benign Prostatic Hyperplasia
  • Acute Urinary Retention
Source: FDA Label
🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

Full development history with FDA approval milestones

Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

PROSCAR FDA Label Details

Pro

Indications & Usage

FDA Label (PDF)

PROSCAR, is a 5α-reductase inhibitor, indicated for the treatment of symptomatic benign prostatic hyperplasia (BPH) in men with an enlarged prostate to : Improve symptoms Reduce the risk of acute urinary retention Reduce the risk of the need for surgery including transurethral resection of the prostate (TURP) and prostatectomy. PROSCAR administered in combination with the alpha-blocker doxazosin is indicated to reduce the risk of symptomatic progression of BPH (a confirmed ≥4 point increase in American Urological Association (AUA) symptom score) . Limitations of Use : PROSCAR is not approved f...

Want competitive intelligence?

See who's developing similar drugs and track their progress

View Pipeline Dashboard

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.